Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track CYTK with free AI briefings, catalyst countdowns, and dilution alerts.

CYTK · CYTOKINETICS INC

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$1.6B Cash on Hand
33.5mo Cash Runway
19.7% Short Interest
$109.42 Analyst Target (19)
Follow CYTK by email Get an email when CYTK reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CYTK, unsubscribe in one click. Privacy

📣 What CYTK Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Aficamten
FDA approved Dec 2025 · Myqorzo
Hypertrophic Cardiomyopathy (HCM) Phase 4 · NCT07600177 Recruiting
Tirasemtiv Amyotrophic Lateral Sclerosis (ALS) Phase 3 · NCT02936635 Completed
Omecamtiv Mecarbil Heart Failure With Reduced Ejection Fraction Phase 3 · NCT03759392 Completed
Reldesemtiv Amyotrophic Lateral Sclerosis Phase 3 · NCT04944784 Terminated
CK-3773274 Hypertrophic Cardiomyopathy (HCM) Phase 2 · NCT04219826 Completed
Ulacamten Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF) Phase 2 · NCT06793371 Recruiting
Omecamtiv Mecarbil Matrix F1 Formulation Modified Release Oral Formulation Phase 2 · NCT01786512 Completed
Omecamtiv Mecarbil Matrix F2 Formulation Modified Release Oral Formulation Phase 2 · NCT01786512 Completed
Omecamtiv Mecarbil Swellable Core Technology F2 Modified Release Oral Formulation Phase 2 · NCT01786512 Completed
KSP Inhibitor SB-743921 Non-Hodgkin's Lymphoma Phase 1/2 · NCT00343564 Completed
CK-1827452 Heart Failure Phase 2 · NCT00624442 Completed
Moxifloxacin QT Intervals Changes Phase 1 · NCT04175808 Completed
AMG 423 Heart Failure Phase 1 · NCT01737866 Completed
Ispinesib Breast Neoplasms Phase 1 · NCT00607841 Terminated
CK-3773274 - Granules in Capsule Symptomatic Obstructive Hypertrophic Cardiomyopathy Phase 1 · NCT03767855 Completed
CK-4021586 Healthy Participants Phase 1 · NCT05877053 Completed

Also used in these trials (approved or third-party drugs, not CYTK's own candidates): Metoprolol Succinate Er, Riluzole.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

CYTK holds $1.6B in cash and short-term investments (as of Sep 30, 2026) and burns about $141.9M/quarter from operations, an estimated runway of 33.5 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 32 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CYTK files for a raise →

👥 Who Owns CYTK

Insiders 0.6% Institutions (658 holders) 99.4% Public and other holders 0%
HolderTypeShares% of sharesAs of
Blackrock Inc. Institution (13F) 21,041,152 15.10% 2026-09-30
T. Rowe Price Investment Management, Inc Institution (13G, 5%+) 17,716,372 12.72% 2025-12-31
Wellington Management Group LLP Institution (13G, 5%+) 10,742,652 7.71% 2026-09-30
Polar Capital Holdings PLC Institution (13F) 9,635,314 6.92% 2026-09-30
STATE STREET CORPORATION Institution (13G, 5%+) 7,143,229 5.13% 2026-09-30
Vanguard Portfolio Management LLC Institution (13F) 6,799,536 4.88% 2026-09-30
Vanguard Capital Management Institution (13G, 5%+) 6,422,042 4.61% 2026-03-31
Avoro Capital Advisors LLC Institution (13F) 4,900,000 3.52% 2026-09-30
Bank of America Corporation Institution (13F) 4,735,328 3.40% 2026-09-30
Geode Capital Management, LLC Institution (13F) 3,767,864 2.70% 2026-09-30
Invesco Ltd. Institution (13F) 3,016,565 2.17% 2026-09-30
Robert I Blum
President & CEO, Director · +247,774 options
Insider 282,710 0.20% 2026-11-02

Share count 139,303,351 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-11-09
filed 2026-11-12
PARSHALL B LYNNE
Sale (S) 2,445 $54.17 8,339
2026-11-09
filed 2026-11-12
PARSHALL B LYNNE
Sale (S) 2,555 $55.26 5,784
2026-11-03
filed 2026-11-03
Malik Fady Ibraham
Option exercise (M) 3,500 $7.80 157,402
2026-11-03
filed 2026-11-03
Malik Fady Ibraham
Sale (S) 3,500 $62.93 153,902
2026-11-03
filed 2026-11-03
Malik Fady Ibraham
Option exercise (M) 3,500 – –

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2026-11-14 aficamten sNDA -12.2% — —
2025-12-26 MYQORZO NDA -4.5% -1.7% -3.8%

Browse all historical PDUFA outcomes →

Get the full CYTK picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CYTK and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.